Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Objectively measured hyperactivity--II. Caffeine and amphetamine effects.

M D Schechter, G D Timmons

    Journal of Clinical Pharmacology
    |May 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Dr. Timmons Urges Dentists To "Step Up and Be Counted".

    Journal of the American Dental Society of Anesthesiology·2009
    Same author

    Radiocontrast interference in screening tests for genetic-metabolic diseases.

    Clinica chimica acta; international journal of clinical chemistry·1999
    Same author

    Continued trends in the conditioned place preference literature from 1992 to 1996, inclusive, with a cross-indexed bibliography.

    Neuroscience and biobehavioral reviews·1998
    Same author

    'Candyflipping': synergistic discriminative effect of LSD and MDMA.

    European journal of pharmacology·1998
    Same author

    Olanzapine attenuates the reinforcing effects of cocaine.

    European journal of pharmacology·1998
    Same author

    MDMA-like stimulus effects of hallucinogens in male Fawn-Hooded rats.

    Pharmacology, biochemistry, and behavior·1998
    Same journal

    Population Pharmacokinetic Modeling and Simulation to Support the Regulatory Submission of the Two-Injection Start Regimen with Aripiprazole Once-Monthly Long-Acting Injectable Intramuscular Administration in Japanese Patients with Schizophrenia or Bipolar I Disorder.

    Journal of clinical pharmacology·2026
    Same journal

    External Evaluation of Population Pharmacokinetic Models for Factor VIII in Chinese Patients with Hemophilia A.

    Journal of clinical pharmacology·2026
    Same journal

    How to Replace the TQT Study-The Use of Concentration-QTc Modeling to Exclude a Small Effect of a Novel Drug on QT Interval: Historical Perspective and Implementation.

    Journal of clinical pharmacology·2026
    Same journal

    Genome Sequencing Enhances Precision and Clinical Utility of Pharmacogenetic Data Compared to Arrays.

    Journal of clinical pharmacology·2026
    Same journal

    FDA Gene Therapy Approvals (1998-2025): Current Status, Regulatory Evolution, and Future Directions.

    Journal of clinical pharmacology·2026
    Same journal

    Human Disposition, Metabolism, and Excretion of Sevasemten (EDG-5506), a Selective Modulator of Fast Myosin in Healthy Volunteers.

    Journal of clinical pharmacology·2026
    See all related articles

    This study found that amphetamine and caffeine treatments significantly reduced errors and improved reaction times in hyperactive children. All tested drug regimens also improved subjective symptoms of hyperactivity.

    Area of Science:

    • Neuroscience
    • Pediatric Psychology
    • Pharmacology

    Background:

    • Hyperactivity, characterized by commission/omission errors and chair movements, impacts children's cognitive function.
    • The Conner's Abbreviated Parent Questionnaire is a tool for assessing hyperactive symptoms.

    Purpose of the Study:

    • To evaluate the efficacy of different drug regimens in managing symptoms of hyperactivity in children.
    • To assess the impact of amphetamine and caffeine on cognitive performance and subjective symptoms.

    Main Methods:

    • Fifteen hyperactive children were tested using the Continuous Performance Test.
    • Four drug regimens were administered: amphetamine (1.6 mg and 5.0 mg BID), caffeine (300 mg BID), and caffeine (300 mg BID) with amphetamine (1.6 mg BID).
    • Performance metrics included errors of commission/omission, chair movements, and reaction times, alongside subjective symptom assessment via the Conner's Abbreviated Parent Questionnaire.

    Related Experiment Videos

    Main Results:

    • Amphetamine and caffeine treatments significantly reduced errors of commission and increased reaction times in children with high scores (≥24) on the Conner's Abbreviated Parent Questionnaire.
    • All drug treatments led to significant reductions in subjective hyperactive symptoms.
    • A high dose of caffeine (600 mg daily) effectively controlled hyperactive symptoms but also caused side effects.

    Conclusions:

    • Amphetamine and caffeine demonstrate efficacy in improving cognitive control and reducing subjective symptoms in hyperactive children.
    • Dosage and combination of treatments influence effectiveness and side effect profiles.
    • Further research into optimized therapeutic strategies for pediatric hyperactivity is warranted.